Metacrine (NASDAQ:MTCR) Upgraded by Zacks Investment Research to Hold

Metacrine stock has undergone multiple analysts rating changes in the recent past.  Metacrine Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Metacrine traded down -$0.03 on Wednesday, reaching $3.56. 0 shares of the stock traded hands, compared to its average volume of 314932. Shares of Metacrine were trading at $3.56 on Wednesday. The firm’s 50 day moving average is $3.14 and its 200 day moving average is $5.28.Metacrine has a 12 month low of $3.47 and a 12 month high of $11.65. While on yearly highs and lows, Metacrine’s today has traded high as $3.66 and has touched $3.47 on the downward trend. See More Analyst Rating at: RATING

Metacrine Earnings and What to expect: 

Metacrine last announced its quarterly earnings results on August 12th, 2021. The reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.01. Metacrine has generated ($3.97) earnings per share over the last year. Earnings for Metacrine are expected to grow in the coming year, from ($2.38) to ($2.13) per share. Metacrine has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for Metacrine are expected to grow in the coming year, from ($2.38) to ($2.13) per share. The P/E ratio of Metacrine is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Metacrine is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Metacrine has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Metacrine (NASDAQ:MTCR) Moving Average Technical Analysis

5 day Moving Average is $3.58 And 5 day price change is -$0.02 (-0.56%)  with average volume for 5 day average is 200,220. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $3.41 and 20 day price change is $0.66 (22.76%) and average 20 day moving volume is 364,925. 50 day moving average is $3.14  and 50 day price change is $0.55 ( 18.27%)  and with average volume for 50 days is : 247,260. 200 day moving average is $5.28  and 200 day price change is -$4.48 (-55.72%)  and with average volume for 200 days is : 157,866.

Other owners latest trading in Metacrine :

  • On 9/17/2021 shares held by Virtu Financial LLC were 19,671 which equates to market value of $75K and appx 0.00% owners of Metacrine
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 55,753 which equates to market value of $0.21M and appx 0.00% owners of Metacrine
  • On 8/23/2021 shares held by Morgan Stanley were 14,699 which equates to market value of $56K and appx 0.00% owners of Metacrine
  • In total Institutional ownership equates to Institutional Ownership Percentage: 46.95% for Metacrine

See More Analyst Rating at: RATING